Telbivudine/Torcitabine (Idenix/Novartis)

Current Opinion in Investigational Drugs

Volumn 5, Issue 2, 2004, Pages 232-241

  Vere Hodge, R Anthony ^a  

^a Vere Hodge Antivirals Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2 DEOXY BETA L ERYTHROPENTAFURANOSYL) 5 METHYL 2,4(1H) PYRIMIDINONE; 1 (2 DEOXY BETA L ERYTHROPENTAFURANOSYL) 5 METHYL 2,4(1H,3H) PYRIMIDINEDIONE; 1-(2-DEOXY-BETA-L-ERYTHROPENTAFURANOSYL)-5-METHYL-2,4(1H)-PYRIMIDINONE; 1-(2-DEOXY-BETA-L-ERYTHROPENTAFURANOSYL)-5-METHYL-2,4(1H,3H)-PYRIMIDINEDIONE; ANTIVIRUS AGENT; NEW DRUG; NUCLEOSIDE; PYRIMIDINONE DERIVATIVE;

ANIMAL; CHEMISTRY; CLINICAL TRIAL; DRUG EFFECT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; METABOLISM; METHODOLOGY; PHARMACEUTICS; REVIEW; STATISTICS;

ANIMALS; ANTIVIRAL AGENTS; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; NUCLEOSIDES; PYRIMIDINONES; TECHNOLOGY, PHARMACEUTICAL;

EID: 3042807040     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. 364489 Anti-hepatitis B specific β-L-2′- deoxynucleosides. Bryant ML, Gosselin G, Schinazi RF, Imbach JL, Sommadossi JP INT CONF ANTIVIRAL RES 2000 13 Abs 67
2. 364575 β-L-2′-deoxynucleosides as potent anti-HBV agents (part I): Large-scale stereospecific synthesis of β-L-2′- deoxyadenosine. Dukhan D, Pierra C, Bryant M, Sommadossi JP, Imbach JL, Gosselin G INT CONF ANTIVIRAL RES 2000 13 Abs 89
3. 364588 β-L-2′-deoxynucleosides as potent anti-HBV agents (part II): Large scale stereospecific syntheses of β-L-thymidine. Pierra C, Dukhan D, Bryant M, Sommadossi JP, Imbach JL, Gosselin G INT CONF ANTIVIRAL RES 2000 13 Abs 90
4. 397171 Antiviral L-nucleosides specific for hepatitis B virus infection. Bryant ML, Bridges EG, Placidi L, Faraj A, Loi AG ANTIMICROB AGENTS CHEMOTHER 2001 45 1 229-235
5. 405816 Synergistic antiviral L-nucleosides specific for hepatitis B virus infection. Juodawlkis A, Bridges E, Cretton SE, Standring D, Benzaria S, Pierra C, Gosselin G, Imbach JL, Tennant B, Korba B, Sommadossi JP, Bryant M ANTIVIRAL RES 2001 50 1 Abs 14
6. 405819 Pharmacokinetics of β-L-2′-deoxycytidine prodrugs in monkeys. Cretton SE, Bridges EG, Zhou XJ, Juodawlkis A, Gosselin G, Imbach JL, Pierra C, Benzaria S, Sommadossi JP, Bryant M ANTIVIRAL RES 2001 50 1 Abs 16
7. 406019 Synthesis of potential prodrugs of β-L-dC, a potent and selective anti-HBV agent. Bezaria S, Pierra C, Imbach JL, Bryant M, Sommadossi JP, Gosselin G ANTIVIRAL RES 2001 50 1 Abs 137
8. 406020 Comparitive studies of selected potential prodrugs of β-L-dC, a potent and selective anti-HBV agent. Pierra C, Benzaria S, Gosselin G, Imbach JL, Bryant M, Sommadossi JP ANTIVIRAL RES 2001 50 1 Abs 138
9. 406048 Toxological evaluation of the anti-HBV agent β-L-deoxythymidine. Bridges EG, Juodawlkis A, Gosselin G, Imbach JL, Sommadossi JP, Bryant M ANTIVIRAL RES 2001 50 1 Abs 146
10. 406913 Antiviral Research 14th International Conference (Part VI), Hepatitis Viruses, Seattle, WA, USA. Smee DF IDDB MEETING REPORT 2001 April 8-13
11. 408263 Novirio secures $44 million in a series C financing. Novirio Pharmaceuticals Inc PRESS RELEASE 2001 May 07
12. 414197 Novirio and Sumitomo Pharmaceuticals announce agreement for hepatitis B drug. Novirio Pharmaceuticals Inc PRESS RELEASE 2001 July 01
13. 433880 Novirio Pharmaceuticals announces results from first human study of LdT for the treatment of hepatitis B infection - phase I/II data presented at the Interscience Conference On Antimicrobial Agents and Chemotherapy (ICAAC). Novirio Pharmaceuticals Inc PRESS RELEASE 2001 December 17
14. 435422 HEP DART 2001 (Part I), Frontiers in Drug Development for Viral Hepatitis, Kapalua, Maui, Hawaii. Dunkle LM IDDB MEETING REPORT 2001 December 16-20
15. 435762 Novirio Pharmaceuticals names George Chao, PhD as Vice President Biostatistics and Data Management. Novirio Pharmaceuticals Inc PRESS RELEASE 2002 January 14
16. 437041 Novirio Pharmaceuticals Ltd. HAMBRECHT & QUIST 2002 January 7-10 432
17. 458973 Pharmacology of β-L-thymidine and β-L-2′- deoxycytidine in HepG2 cells and primary human hepatocytes: Relevance to chemotherapeutic efficacy against hepatitis B virus. Hernandez Santiago B, Placidi L, Cretton SE, Faraj A, Bridges EG, Bryant ML, Rodgriguez Orengo J, Imbach JL, Gosselin G, Pierra C, Dukhan D, Sommadossi JP ANTIMICROB AGENTS CHEMOTHER 2002 46 6 1728-1733
18. 458975 In vitro cross-resistance testing of adefovir, entecavir, and β-L-thymidine (L-DT) against drug-resistant strains of HBV. Delany WE, Yang H, Westland CE, Lin KY, Miller MD, Gibbe CS, Xiong S HEPATOLOGY 2001 34 4 Pt 2 628A
19. 460857 Antiviral β-L-nucleosides specific for hepatitis B virus infection. Standring DN, Bridges EG, Placidi L, Faraj A, Loi AG, Pierra C, Dukhan D, Gosselin G, Imbach JL, Hernandez B, Juodawlkis A et al ANTIVIRAL CHEM CHEMOTHER 2001 12 Suppl 1 119-129
20. 462525 Drug development pipeline: Idenix Pharmaceuticals. Idenix Pharmaceuticals Inc COMPANY COMMUNICATION 2002 August 22
21. 462644 Anti-HBV specific β-L-2′-deoxynucleosides. Bryant ML, Bridges EG, Placidi L, Faraj A, Loi AG, Pierra C, Dukhan D, Gosselin G, Imbach JL, Hernandez B, Juodawlkis A et al NUCLEOSIDES NUCLEOTIDES NUCLEIC ACIDS 2001 20 4-7 597-607
22. 463285 Hepatitis B. Idenix Pharmaceuticals Inc COMPANY WORLD WIDE WEB SITE 2002 September 09
23. 464238 A phase I/II dose escalating trial evaluating safety, tolerability, pharmacokinetics and antiviral activity of clevudine in chronic HBV-infected patients (L-FMAU-102). Lee H, Marin HM, Sacks S, Sereni D, Bronowicki J, Conway B, Zarski J, Rousseau F, Mondou E, Snow A, Blum R et al ICAAC 2002 42 Abs V689
24. 475756 Idenix Pharmaceuticals presents corporate and clinical progress at the 21st Annual JP Morgan H&Q Healthcare Conference. Idenix Pharmaceuticals Inc PRESS RELEASE 2003 January 08
25. 476555 Idenix Pharmaceuticals. HAMBRECHT & QUIST 2003 January 6-9
26. 482521 Entecavir pharmacokinetics after multiple doses in healthy subjects. Yan JH, Bifano M, Nichola P, O'Mara E, Loizillon E, Zhang D, Olsen S J CLIN PHARMACOL 2002 42 9 1070 Abs 86
27. 482527 Rational dose identification of entecavir for chronic hepatitis B infection based on prospective evaluation of in vitro, animal model, clinical pharmacology, and human clinical trial data. DeHertogh D, Colonno R, Thomas N, Olsen S, Kreter B HEPATOLOGY 2002 36 4 Pt 2 637a
28. 483669 Novartis Pharma AG and Idenix Pharmaceuticals Inc jointly build major antiviral therapeutic franchise. Idenix Pharmaceuticals Inc PRESS RELEASE 2003 March 26
29. 488843 Antiviral Research - 16th International Conference (Part I), HBV and HCV, Savannah, GA, USA. Smee D IDDB MEETING REPORT 2003 April 27-May 1
30. 489012 Novartis and Idenix Pharmaceuticals Inc announce successful closing of strategic alliance Novartis AG PRESS RELEASE 2003 May 09
31. 491099 Exane Pharma Seminar, Paris: Outperforming the market - investing in the future. Novartis AG COMPANY PRESENTATION 2003 May 22
32. 494552 Gilead and Bukwang end licensing agreement for Clevudine, investigational agent for chronic hepatitis B. Gilead Sciences Inc PRESS RELEASE 2003 June 24
33. 505622 Nucleic acid components and their analogs. CLIII. Preparation of 2 deoxy-L-ribonucleosides of the pyrimidine series. Holy A COLL CZECH CHEM COMMUN 1972 37 4072-4087
34. 513706 Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF HEPATOLOGY 2001 33 3 751-757
35. 513820 Second-phase viral clearance as a measure for dose optimization of anti-HBV nucleosides. Lia CL, Zhou XJ, Brown N, Myers M, Lloyd D, Lim SG J HEPATOL SUPPL 2002 36 S1 Abs 462
36. 513826 Val-LdC: First evidence of efficacy and safety for a new anti-HBV agent. Lim SG, Lai CL, Dan YY et al GASTROENTEROLOGY 2002 122 A628 Abs 87
37. 513833 β-L-2′-Deoxythymidine and 3′-O- L-valinyl ester of β-L-2′-deoxycytidine: two potent and selective anti-HBV drugs. Gosselin G ANTIVIRAL RES 2003 57 3 12
38. 513844 Results of a one-year international phase IIb comparative trial of LdT, lamivudine, and the combination, in patients with chronic hepatitis B. Lai CL, Leung NWY, Teo EK, Tong M, Wong F, Hann HW, Han S, Poynard T, Myers M, Chao G, Lloyd D, Brown N HEPATOLOGY 2003 38 4 Suppl 1 Abs 219
39. 513846 A phase IIb comparative trial of LdT, lamivudine and the combination in hepatitis B patients: Greater antiviral effect with LdT. Lai CL, Leung N, Teo EK, Tong M, Wong F, Hann HW, Han S, Poynard T, Myers M, Chao G, Lloyd D, Brown N ICAAC 2003 43 Abs V-1723
40. 513849 In vitro evaluation of combination therapies against hepatitis B virus replication. Korba BE ANTIVIRAL RES 1996 29 1 49-51
41. 513850 International multicenter trial of LdT (telbivudine), alone and in combination with lamivudine, for chronic hepatitis B: An interim analysis. Lai CL, Leung N, Teo EK et al HEPATOLOGY 2002 36 4 Pt 2 Abs 554
42. 513950 Presentations & events: R&D Day presentation (November 19, 2003 - New York, NY, USA). Novartis AG COMPANY PRESENTATION 2003 November 19
43. 519344 Safety and antiviral effects of val-L-dC and L-dT in patients with chronic hepatitis B. Lim SG et al J GASTROENTEROL HEPATOL 2002 17 Suppl
44. 519625 Antiviral activities of β-L-thymidine (LdT), val-β-L-2′-deoxycytidine (val-LdC), and lamivudine alone and in combination in a 12 week, oral dose study using the woodchuck model of chronic hepatitis B virus infection. Tennant B HEP DART: FRONTIERS DRUG DEV VIRAL HEPATITIS 2001 December 16-20